[go: up one dir, main page]

WO2009060473A3 - Injectable compositions, processes and uses thereof - Google Patents

Injectable compositions, processes and uses thereof Download PDF

Info

Publication number
WO2009060473A3
WO2009060473A3 PCT/IN2008/000757 IN2008000757W WO2009060473A3 WO 2009060473 A3 WO2009060473 A3 WO 2009060473A3 IN 2008000757 W IN2008000757 W IN 2008000757W WO 2009060473 A3 WO2009060473 A3 WO 2009060473A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
pharmaceutically acceptable
processes
injectable compositions
biocompatible
Prior art date
Application number
PCT/IN2008/000757
Other languages
French (fr)
Other versions
WO2009060473A2 (en
Inventor
Rajesh Jain
Sukhjeet Singh
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Limited filed Critical Panacea Biotec Limited
Publication of WO2009060473A2 publication Critical patent/WO2009060473A2/en
Publication of WO2009060473A3 publication Critical patent/WO2009060473A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Injectable depot gel or implant compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s) are provided. The present invention also describes process for preparation of such compositions and method of using such compositions.
PCT/IN2008/000757 2007-11-06 2008-11-06 Injectable compositions, processes and uses thereof WO2009060473A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2321DE2007 2007-11-06
IN2321/DEL/2007 2007-11-06

Publications (2)

Publication Number Publication Date
WO2009060473A2 WO2009060473A2 (en) 2009-05-14
WO2009060473A3 true WO2009060473A3 (en) 2009-10-15

Family

ID=40626309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000757 WO2009060473A2 (en) 2007-11-06 2008-11-06 Injectable compositions, processes and uses thereof

Country Status (3)

Country Link
AR (1) AR070033A1 (en)
CL (1) CL2008003305A1 (en)
WO (1) WO2009060473A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226485B2 (en) 2018-06-12 2025-02-18 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004057959A2 (en) 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) * 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
ES2390439B1 (en) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PL2394663T3 (en) * 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
SI2394664T1 (en) * 2010-05-31 2016-10-28 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
JP5966228B2 (en) * 2010-10-28 2016-08-10 アエクース ファーマシューティカルズ インコーポレイテッドＡｅｑｕｕｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ Aripiprazole composition
ES2939744T3 (en) 2010-12-29 2023-04-26 Medincell S A Biodegradable Drug Release Compositions
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
LT2685979T (en) 2011-03-18 2016-12-12 Alkermes Pharma Ireland Limited Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
EP3219310A3 (en) * 2011-10-24 2017-11-29 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
TWI583401B (en) 2011-10-24 2017-05-21 布雷本製藥股份有限公司 Implantable tizanidine compositions and methods of treatment thereof
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
NZ630703A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
EP2827866B1 (en) * 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160022571A1 (en) * 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
CN106132415A (en) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 There is the aripiprazole formulations of the injection speed of increase
US11129940B2 (en) 2014-08-06 2021-09-28 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
CN104189954B (en) * 2014-09-19 2017-03-29 中国科学院长春应用化学研究所 A kind of in-situ solidifying tissue engineering bracket and preparation method thereof
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
AU2016302252B2 (en) * 2015-08-03 2022-01-20 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
PT3377041T (en) 2015-11-16 2023-12-15 Maria Pereira Da Cruz Alves Garcia A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
KR102033686B1 (en) 2017-05-19 2019-10-18 보령제약 주식회사 Microneedle transdermal patch comprising donepezil
CA3064840A1 (en) 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
GB2568526A (en) * 2017-11-20 2019-05-22 Rebio Tech Oy Composition
CN112423754A (en) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 Aripiprazole administration strategy
UY38386A (en) * 2018-09-25 2020-04-30 Tolmar Int Ltd LIQUID POLYMER DELIVERY SYSTEM FOR PROLONGED ADMINISTRATION OF DRUGS
US11911499B2 (en) * 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN113209370B (en) * 2020-01-21 2023-11-28 渼颜空间(河北)生物科技有限公司 Biodegradable injection filler, preparation method and application thereof
JP2024527531A (en) * 2021-06-30 2024-07-25 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Injectable, biodegradable and removable polymer-based drug suspensions for ultra-long-acting drug delivery
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
JP2024546571A (en) * 2021-12-24 2024-12-26 シチュアン ケルン ファーマシューティカル リサーチ インスティテュート カンパニー リミテッド Stable release sustained release delivery formulation and its manufacturing method
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
WO2025051282A1 (en) * 2023-09-08 2025-03-13 广州玻思韬控释药业有限公司 Gel for injection

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950403A2 (en) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsions for in-situ delivery systems
WO2000024374A1 (en) * 1998-10-28 2000-05-04 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2008041245A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
EP0950403A2 (en) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsions for in-situ delivery systems
WO2000024374A1 (en) * 1998-10-28 2000-05-04 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2008041245A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226485B2 (en) 2018-06-12 2025-02-18 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition

Also Published As

Publication number Publication date
AR070033A1 (en) 2010-03-10
CL2008003305A1 (en) 2009-06-05
WO2009060473A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
WO2009060473A3 (en) Injectable compositions, processes and uses thereof
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2003062248A3 (en) N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003073986A3 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
NO20076288L (en) Pharmaceutical compositions including imatinib and a release-lowering agent
WO2007002635A3 (en) C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
MX2009012847A (en) Dipeptide analogs as coagulation factor inhibitors.
WO2004112710A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
WO2004058149A3 (en) 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
TNSN07490A1 (en) Pharmaceutical sustained release compositions and processes thereof
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2003074008A3 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
WO2011003018A3 (en) Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
WO2008039489A3 (en) 5-substituted quinazolinone derivatives as antitumor agents
WO2005032465A3 (en) 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
DE602006011752D1 (en) PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES SUITABLE AS ANTICOAGULATING AGENTS
WO2008157751A3 (en) Substituted imidazoheterocycles
SI1635731T1 (en) Method of preventing surgical adhesions
WO2010011821A3 (en) Dual-acting antihypertensive agents
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
IN2014KN02886A (en)
UA91129C2 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2178869A4 (en) INDOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS
NO20080186L (en) Heterocyclic aspartyl protease inhibitors, preparation and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08846791

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08846791

Country of ref document: EP

Kind code of ref document: A2